National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® and NCCN Compendium® Updated

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL). These NCCN Guidelines® are currently available as Version 1.2017.

  • Workup (WM/LPL-1)
    • Added “CXCR4 gene testing for patients being considered for ibrutinib” with a new footnote.
      • New footnote, “Studies have shown that mutations in this gene are found in up to 40% of patients with WM/LPL and can impact ibrutinib response.”
  • Relapse (WM/LPL-2)
    • For relapsed disease, to choose between alternate therapy or therapy used previously, the time taken into consideration was changed from 12 to 24 months.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)
275 Commerce Drive, Suite 300
Fort Washington, PA 19034
Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

 

© 2017 National Comprehensive Cancer Network. All Rights Reserved.

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL). These NCCN Guidelines® are currently available as Version 1.2017.

  • Workup (WM/LPL-1)
    • Added “CXCR4 gene testing for patients being considered for ibrutinib” with a new footnote.
      • New footnote, “Studies have shown that mutations in this gene are found in up to 40% of patients with WM/LPL and can impact ibrutinib response.”

 

  • Relapse (WM/LPL-2)
    • For relapsed disease, to choose between alternate therapy or therapy used previously, the time taken into consideration was changed from 12 to 24 months.

 

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

 

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

 

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

 

About NCCN Flash Updates™ 

 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

 

Subscribe to NCCN Flash Updates™ 

 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

 

Access information on permissions and licensing of NCCN Content  

 

© 2017 National Comprehensive Cancer Network. All Rights Reserved.